Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires $16,488.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 13,740 shares of MAIA Biotechnology stock in a transaction that occurred on Friday, December 5th. The stock was acquired at an average price of $1.20 per share, for a total transaction of $16,488.00. Following the transaction, the director directly owned 4,580 shares of the company’s stock, valued at $5,496. The trade was a -150.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Stan Smith also recently made the following trade(s):

• On Tuesday, November 25th, Stan Smith acquired 15,000 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $0.98 per share, with a total value of $14,700.00.
• On Monday, November 24th, Stan Smith bought 10,000 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $0.99 per share, for a total transaction of $9,900.00.
• On Wednesday, October 1st, Stan Smith bought 19,230 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.30 per share, for a total transaction of $24,999.00.

MAIA Biotechnology Trading Up 18.8%

MAIA opened at $1.64 on Friday. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.53. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $2.74. The firm has a market cap of $60.73 million and a P/E ratio of -2.25.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MAIA. Centerpoint Advisory Group bought a new stake in shares of MAIA Biotechnology in the 2nd quarter worth about $28,000. Marshall Wace LLP bought a new stake in MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $52,000. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management raised its holdings in shares of MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after buying an additional 505,150 shares during the period. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.